Allakos Inc. (ALLK) |
|
7.58 -0.37 (-4.65%)
|
12-07 16:00 |
|
Open: |
7.92 |
Pre. Close: |
7.95 |
|
High:
|
7.98 |
Low:
|
7.3209 |
|
Volume:
|
687,127 |
Market Cap:
|
646(M) |
|
|
|
Technical analysis |
as of: 2022-12-07 4:20:14 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 10.06 One year: 11.75 |
| Support: |
Support1: 6.72 Support2: 5.55 |
| Resistance: |
Resistance1: 8.61 Resistance2: 10.06 |
| Pivot: |
7.69  |
| Moving Average: |
MA(5): 8.05 MA(20): 7.56
MA(100): 5.47 MA(250): 6.84 |
| MACD: |
MACD(12,26): 0.4 Signal(9): 0.4 |
| Stochastic oscillator: |
%K(14,3): 57.6 %D(3): 69.8 |
| RSI: |
RSI(14): 55.1 |
| 52-week: |
High: 86.94 Low: 2.53 |
| Average Vol(K): |
3-Month: 1,564 (K) 10-Days: 915 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ALLK ] has closed above bottom band by 42.7%. Bollinger Bands are 7.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
8 - 8.05 |
8.05 - 8.08 |
|
Low:
|
7.21 - 7.27 |
7.27 - 7.32 |
|
Close:
|
7.5 - 7.59 |
7.59 - 7.66 |
|
Company Description |
|
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California. |
Headline News |
Tue, 29 Nov 2022
Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology - Yahoo Finance
Sat, 26 Nov 2022
Allakos Inc. (NASDAQ:ALLK) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Thu, 10 Nov 2022
FY2022 Earnings Forecast for Allakos Inc. Issued By Cantor Fitzgerald (NASDAQ:ALLK) - MarketBeat
Thu, 10 Nov 2022
Allakos (ALLK) Presents Preclinical Data on AK007 - StreetInsider.com
Tue, 08 Nov 2022
IceCure, Allakos top healthcare gainers; NanoString, R1 RCM lead losers' pack - Seeking Alpha
Tue, 08 Nov 2022
Allakos Earnings Beat, Revenue In line In Q3 By Investing.com - Investing.com
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
85 (M) |
| Shares Float |
41 (M) |
|
% Held by Insiders
|
4.3 (%) |
|
% Held by Institutions
|
87.2 (%) |
|
Shares Short
|
3,260 (K) |
|
Shares Short P.Month
|
4,140 (K) |
Stock Financials |
|
EPS
|
-7.6 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
4.03 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-43.7 |
|
Return on Equity (ttm)
|
-85.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-4.19 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-299 (M) |
|
Levered Free Cash Flow
|
-197 (M) |
Stock Valuations |
|
PE Ratio
|
-1 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
1.87 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-2.17 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
